2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Chung-Cheng Liu

Session 4 – Combating Pandemics (A)
Date: 22 July (Wednesday) 14:00 – 15:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Chung-Cheng Liu

President/General Manager
Adimmune Corp.



 

Trained as a Ph.D. biochemist in Dr. Bruce Alberts’ lab at Princeton University and later as postdoctoral fellow at UCSF.  Joined Adimmune in December, 2012 as General Manager/President, also served as Chairman of Enimmune corp, a subsidiary of Adimmune Corp. in 2019.  Dr. Liu was at ITRI of Taiwan between 1999 and 2012 serving as Divisional Director, Deputy General Director, and General Director of Biomedical Engineering Research Lab and VP of ITRI.  Before returning to Taiwan in 1999, Dr. Liu has worked at Genentech Inc, Pharmacia Genetic Engineering Inc., and Genencor International as research scientist and research director since leaving UCSF in 1980.  Dr. Liu is a native of Taiwan and graduated from Department of Zoology (now Life Science) of National Taiwan University.


Speech title & Synopsis

How a Vaccine Manufacturer Excel in an Era of Pandemics?

Adimmune is the leading human vaccine manufacturer in Taiwan and is the only company in Asia to hold cGMP certificate from both US FDA and EMA for fill-n-finish platform. We are the co-manufacturer of Flublok (US, with Sanofi) and Enoxaparin (EU, with Techdow).  With a state-of-art flu vaccine facility, we provide more than half of the vaccination needs in Taiwan and also sell them in mainland China. With multiple technology platforms, we are capable of making human vaccine in different formats.

With the news of potential new corona virus outbreak in China late last year, we started evaluating the best way for us to prepare a vaccine for it and quickly settled on the subunit vaccine design which is produced in a baculoviral vector in Sf-9 insect cell line. This approach has several advantages that I will discuss in my presentation.  At present, we have demonstrated the vaccine efficacy in vitro and is conducting the challenge experiment in vivo.  We have successfully produced a clinical batch and is ready to start human clinical evaluation as soon as the regulatory agency in Taiwan completed its evaluation. 

Because of the great success in prevention strategy achieved by our health authority, it will not be easy to conduct efficacy trial in Taiwan.  We are looking for partners in area where an efficacy trial is more likely to succeed.  We have also engaged local partners for large scale production in the range of 30-40 million doses a year if needed.

​​